164 related articles for article (PubMed ID: 34445656)
1. Molecular Iodine/Cyclophosphamide Synergism on Chemoresistant Neuroblastoma Models.
Álvarez-León W; Mendieta I; Delgado-González E; Anguiano B; Aceves C
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445656
[TBL] [Abstract][Full Text] [Related]
2. Molecular iodine synergized and sensitized neuroblastoma cells to the antineoplastic effect of ATRA.
Mendieta I; Rodríguez-Gómez G; Rueda-Zarazúa B; Rodríguez-Castelán J; Álvarez-León W; Delgado-González E; Anguiano B; Vázquez-Martínez O; Díaz-Muñoz M; Aceves C
Endocr Relat Cancer; 2020 Dec; 27(12):699-710. PubMed ID: 33112807
[TBL] [Abstract][Full Text] [Related]
3. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
5. Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts.
Mendieta I; Nuñez-Anita RE; Nava-Villalba M; Zambrano-Estrada X; Delgado-González E; Anguiano B; Aceves C
BMC Cancer; 2019 Mar; 19(1):261. PubMed ID: 30902074
[TBL] [Abstract][Full Text] [Related]
6. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
Chen Z; Wang L; Yao D; Yang T; Cao WM; Dou J; Pang JC; Guan S; Zhang H; Yu Y; Zhao Y; Wang Y; Xu X; Shi Y; Patel R; Zhang H; Vasudevan SA; Liu S; Yang J; Nuchtern JG
Sci Rep; 2016 Dec; 6():38011. PubMed ID: 27991505
[TBL] [Abstract][Full Text] [Related]
7. Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model.
Morscher RJ; Aminzadeh-Gohari S; Hauser-Kronberger C; Feichtinger RG; Sperl W; Kofler B
Oncotarget; 2016 Mar; 7(13):17060-73. PubMed ID: 26959744
[TBL] [Abstract][Full Text] [Related]
8. Direct Targeting of
Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
MacFarland SP; Naraparaju K; Iyer R; Guan P; Kolla V; Hu Y; Tan K; Brodeur GM
Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
[TBL] [Abstract][Full Text] [Related]
10. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
11. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
12.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
13. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
14. Molecular iodine inhibits the expression of stemness markers on cancer stem-like cells of established cell lines derived from cervical cancer.
Bigoni-Ordóñez GD; Ortiz-Sánchez E; Rosendo-Chalma P; Valencia-González HA; Aceves C; García-Carrancá A
BMC Cancer; 2018 Sep; 18(1):928. PubMed ID: 30257666
[TBL] [Abstract][Full Text] [Related]
15. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
16. RNA N
Cheng J; Xu L; Deng L; Xue L; Meng Q; Wei F; Wang J
Sci Rep; 2020 Aug; 10(1):13624. PubMed ID: 32788584
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.
Soriano A; París-Coderch L; Jubierre L; Martínez A; Zhou X; Piskareva O; Bray I; Vidal I; Almazán-Moga A; Molist C; Roma J; Bayascas JR; Casanovas O; Stallings RL; Sánchez de Toledo J; Gallego S; Segura MF
Oncotarget; 2016 Feb; 7(8):9271-87. PubMed ID: 26824183
[TBL] [Abstract][Full Text] [Related]
18.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
19. Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus.
McGuire TR; Coulter DW; Bai D; Sughroue JA; Li J; Yang Z; Qiao Z; Liu Y; Murry DJ; Chhonker YS; McIntyre EM; Alexander G; Sharp JG; Li R
BMC Cancer; 2019 Aug; 19(1):837. PubMed ID: 31455317
[TBL] [Abstract][Full Text] [Related]
20. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
